Trial Profile

A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
Indications Oropharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

08 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
05 Jul 2016 Planned End Date changed from 1 Sep 2023 to 1 Aug 2024.
05 Jul 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Aug 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com